Cullinan Therapeutics
About
Cullinan Therapeutics is a clinical-stage biotechnology company in Cambridge developing therapies for autoimmune diseases and cancer. It describes its approach as uniting scientific expertise, strategic risk-taking, and rigorous decision-making, and it aims for a future in which people living with these conditions spend less time managing them and more time on what matters most to them and their loved ones.
The company draws on deep expertise in immune modulation and deliberately advances only the molecules it considers most promising, targeting areas of high unmet need. Its most advanced program is zipalertinib, a cancer therapy that has been studied together with chemotherapy in the Phase 3 REZILIENT3 trial. Cullinan is also developing T cell engager therapies, and it has highlighted milestones for that work in the fourth quarter of 2026.
What to Know
- A new drug application for zipalertinib was initiated under the FDA’s Real-Time Oncology Review program.
- REZILIENT3 results were announced at the 2026 World Conference on Lung Cancer.
- It is a member of the Kendall Square Association.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.